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Heparins attenuate cancer metastasis: are selectins the link?
Abstract
Heparin is often used to prevent or treat thromboembolism in cancer patients. Clinical and experimental
evidence suggest that heparin also has anti-cancer activities. Experimental evidence consistently
supports the ability of heparin to attenuate metastasis. The potential anti-metastatic effects of heparin
include the inhibition of cell-cell interactions or heparanase and modulation of growth factors and
anticoagulant activity. Heparin inhibits selectin-mediated interactions of tumor cells with leukocytes,
platelets and endothelial cells, which are likely to mediate the initial steps of hematogenous metastasis.
Prospective clinical trials can be designed based on the insights obtained from experimental studies.
1 
 
 
 
Manuscript 
 
 
Heparins attenuate cancer metastasis 
Are selectins the link? 
 
Heinz Läubli and Lubor Borsig 
Institute of Physiology, University of Zürich, Zürich, Switzerland  
Zürich Center for Integrative Human Physiology 
 
 
 
Corresponding author: Lubor Borsig  
 Institute of Physiology 
 University of Zürich 
 Winterthurerstrasse 190 
 CH-8057 Zürich 
 Switzerland 
 Tel: +41 44 635 5134 
 Fax: +41 44 635 6814 
 Email: lborsig@access.uzh.ch 
 
 
Keywords: heparin, glycosaminoglycans, adhesion molecules, metastasis, P-selectin, selectin 
ligands,  
2 
 
Abstract 
Heparin is often used to prevent or treat thromboembolism in cancer patients. Clinical 
and experimental evidence suggest that heparin also has anti-cancer activities. 
Experimental evidence consistently supports the ability of heparin to attenuate 
metastasis. The potential anti-metastatic effects of heparin include the inhibition of 
cell-cell interactions or heparanase and modulation of growth factors and 
anticoagulant activity. Heparin inhibits selectin-mediated interactions of tumor cells 
with leukocytes, platelets and endothelial cells, which are likely to mediate the initial 
steps of hematogenous metastasis. Prospective clinical trials can be designed based 
on the insights obtained from experimental studies. 
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 I Cancer-Thrombosis-Heparin 
Thromboembolic events are frequent complications in cancer patients and represent 
a major reason of morbidity and mortality (1-3). The hypercoagulable state often 
observed in cancer patients is either activated by the tumor itself or due to anticancer 
treatment-related factors. Several molecular pathways leading to this procoagulant 
state were identified and are thoroughly reviewed elsewhere (e.g. see reviews 4, 5), 
Tissue factor (TF), a main inducer of the coagulation cascade, is upregulated either 
by oncogenic activation or the loss of tumor suppressors in tumor cells and in 
activated endothelial cells within the tumor stroma (6, 7). Recently, a novel 
mechanism was described, which links the MET oncogene to an increased 
expression of COX-2 and PAI-1, thereby inducing a procoagulant state (8). PAI-1 and 
TF are also upregulated in hypoxic areas of tumors, thus suggesting a connection 
between the HIF pathway and hemostasis (9). Moreover, mucins of 
adenocarcinomas were shown to activate the hemostatic system via selectin-
mediated interactions between leukocytes and platelets (10). Standard anticoagulant 
therapy of cancer patients which experience thromboembolism or receive 
chemotherapy are mostly treated with heparin or oral vitamin K antagonist. Low-
molecular weight heparin therapy was shown to be associated with an improved 
survival of cancer patients (1, 11-14). 
Heparin is a natural glycosaminoglycan molecule and consists of N- and O-sulfated 
alternating galactosamine/glucosamine and glucoronic/iudoronic acid carbohydrate 
moieties (15). Unfractionated heparin (UFH) is isolated from porcine intestine and 
represents a very heterogeneous mixture of polymers containing of about 200-300 
monosaccharides. Depolymerisation and fractionation of UFH results in the 
generation of low molecular weight heparin (LMWH) with more constrained biological 
activity (15). Importantly, the characterization of the antithrombin binding 
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pentasaccharide sequence led to the identification of the heparin active site (15). 
Many activities of heparin are known to affect the biology of tumor cells, but only a 
few of them are relevant in vivo (16-19). In this review, we will discuss the in vivo 
activities of heparin on tumor progression, with a special emphasis on the inhibition of 
selectin-mediated cell-cell interactions and heparanase activity during hematogenous 
dissemination. 
 
II Heparin as cancer treatment: Impact on patient survival 
Heparin is commonly used for the prevention or treatment of venous 
thromboembolism. Its effect on tumor progression in cancer patients, however, 
remains controversial. The positive effect of heparin on survival of cancer patients 
was evaluated in several clinical studies and excellently reviewed elsewhere (e.g. 
see reviews 13, 14). 
Several prospective, randomized and placebo-controlled studies were specifically 
planned to analyze heparin as an anti-cancer drug. One such multicenter trial 
involving 138 patients with small lung cancer demonstrated a significant reduction of 
mortality and increased complete response rate in the group treated with UFH 
subcutaneously over a period of 5 weeks (20). In another study by Altinbas and 
colleagues, small lung cancer patients (n=84) were treated with dalteparin or placebo 
in parallel to normal chemotherapy regimens (21). The group treated with 
chemotherapy and dalteparin had a significantly prolonged median survival. 
However, no significant differences were observed in advanced cancer patients 
treated with nadroparin for 2 years (n=138), (22). Although a trend towards an 
increased survival in the nadroparin group could be determined. In the FAMOUS 
study of Kakkar and associates 374 patients with advanced malignancies (Stage III, 
IV) were treated with dalteparin over a period of 1 year. After 3 years, the dalteparin 
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group showed a higher survival rate, albeit not significantly (p=0.19). Interestingly, a 
not a priori defined subgroup analysis of patients with an initial better prognosis 
resulted in a significantly improved survival of the dalteparin treated patients (23). 
The MALT study was conducted to test the effect of a 6 week treatment with 
nadroparin on the survival of patients with advanced cancer of various origins 
(n=302) (24). Nadroparin treatment led to an improvement of survival by 12% after 
one year and 10% after two years (p=0.021). These subgroup analyses of patients 
with better prognosis in the FAMOUS and the MALT studies make heparin an 
interesting candidate to be tested during early stages of cancer. Meta-analysis of all 
patients, including those in above mentioned studies, demonstrated a significant 
improvement of the survival in the LMWH treated group (13, 25). 
The CLOT study was designed to compare the effect of LMWH or oral 
anticoagulation on the prevention of recurrent venous thromboembolism in cancer 
patients with acute venous thrombosis or pulmonary embolism (26, 27). A treatment 
with nadroparin for six months was significantly more effective than oral 
anticoagulation (26). A posthoc analysis in a subgroup of patients without metastases 
resulted in the detection of an increased survival in the dalteparin treated arm of the 
study (27). In contrast to heparin treatment, other studies using coumarin derivatives 
in cancer patients failed to show any decrease in mortality (13, 14). 
Based on these promising results together with observations from animal models, 
heparin seems to directly affect cancer progression. Meanwhile, animal models help 
to study and to validate the activity of heparin during metastasis.  
 
III Heparin attenuates metastasis in mouse models  
Several animal models were used to test heparins as a potential anti-cancer 
treatment. Most of the available experimental data have been obtained in 
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experimental metastasis models, where tumor cells are inoculated directly into the 
blood circulation. Despite several limitations, this approach allows the analysis of the 
cellular events between tumor cells and their microenvironment during the 
hematogenous phase of metastatic colonization. This experimental setting enables 
the evaluation of heparin treatment according to the timely defined molecular events 
and thereby makes it possible to narrow down the potential mechanism. However, 
several aspects of metastasis including lymphatic dissemination, local tumor invasion 
and intravasation can be better examined in spontaneous metastasis models. For 
more than 40 years, UFH was repeatedly shown to reduce experimental and 
spontaneous metastasis in rodents (for review see (17, 19). Because UFH consists of 
highly heterogeneous polysaccharide chains with a wide variety of biological 
activities, the determination of the molecular mechanisms responsible for the anti-
metastatic effect was difficult (17, 28). A first hint was derived from spontaneous 
metastasis models that showed that the primary tumor size was only minimally 
affected, while metastasis was clearly reduced (17, 29). This observation led to the 
conclusion that metastasis rather than tumor growth is inhibited by heparin treatment. 
Many mouse studies analyzing the effect of heparin on metastasis have been 
reported (for review see (17, 19). In these studies, different tumor cells, including 
human and mouse carcinoma and melanoma cells were used, and a variety of 
heparins, including UFH, various low molecular weight heparins (LMWHs) and 
chemically modified heparins were evaluated. While the method of application as well 
as the time period of heparin treatment varied among these studies, the anti-
metastatic effect of heparin treatment was observed mostly in situations when 
heparin was applied when tumor cells were still in circulation. In general, a bolus 
injection of heparin or LMWH prior to tumor cell application was shown to attenuate 
metastasis of colon, lung and breast carcinoma, as well as melanoma (28, 30-34). In 
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all these studies the applied concentration of heparins exceeded the therapeutical 
doses. Nevertheless, recent studies have confirmed that also clinically relevant doses 
of UFH and LMWHs efficiently attenuated experimental metastasis (35, 36).  
 
IV “Anti-cancer” activity of heparin 
Heparin is a complex mixture of glycosaminoglycans containing a variety of biological 
activities. Although clinical preparations of heparin are enriched for its ability to inhibit 
coagulation, heparin also contains activity to: block P- and L-selectins, alter integrin 
binding, affect activity of growth factors and cytokines, inhibit heparanase and 
angiogenesis, modulate the activity of proteases and thereby the components of 
extracellular matrix (15, 17, 18, 37-40). While any of these activities could potentially 
affect cancer progression, all the experimental evidence strongly suggests that 
heparin is likely affecting the early steps of metastasis. Hematogenous metastasis 
consists of cascade of events in which metastatic tumor cells enter the blood 
circulation, evade immune responses, adhere to the endothelium of distant organs 
and extravasate. The observation that a single injection of heparin at the time of 
tumor cell injection attenuates metastasis (30, 31) indicates that selectins, which can 
mediate the initial cell-cell interactions among tumor cells, platelets, leukocytes and 
endothelium, contribute by initiating the process of metastasis. Furthermore, no 
benefit of prolonged heparin treatment over the single heparin injection could be 
observed (41). Considering the relatively short half-life (4-6 h) of heparin in 
circulation, several other activities of heparin (e.g. effects on angiogenesis or growth 
inhibition) are not likely to affect the early steps of metastasis.  
 
V Anticoagulant activity of heparin and metastasis 
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The use of heparin in cancer management indicated effects seemingly unrelated to 
its anticoagulant properties (37, 42, 43). Heparin effect on metastasis was also 
demonstrated in animal models and confirmed to be additional to its anticoagulant 
activity (17, 44). In addition the capacity of heparin to release TFPI from the 
vasculature was shown to affect metastasis (41). Non-anticoagulant heparin 
derivatives were shown to attenuate experimental metastasis, thus confirming that 
the effect on the coagulation system is rather limited with respect to the other anti-
metastatic properties of heparin (29, 30, 34, 45-48). Experimental studies have 
shown that the use of an anti-thrombin inhibitor, hirudin, reduces metastasis (49, 50). 
However, in both these studies the amount used of hirudin resulted in an excessive 
anticoagulation, which is not compatible with clinical applications. Finally, the 
pentasaccharide fondaparinux, which specifically inhibits antithrombin did not reduce 
metastasis in mice at clinically tolerable levels (35, 36).  
 
VI Heparin inhibits heparanase 
A critical event in cancer progression is the invasion of cancer cells into the 
surrounding tissue, which is associated with their capacity to degrade the various 
components of extracellular matrix, including collagen, fibronectin and heparan 
sulfate proteoglycans. Cancer cells produce several hydrolytic enzymes such as 
matrix metalloproteinases and heparanase. Heparanase have an endoglycosidase 
activity and cleave heparan sulfates. Elevated heparanase expression is associated 
with cancer progression of several carcinomas including colon, liver, pancreas, 
bladder, breast and prostate carcinoma as well as leukemia and multiple myeloma 
(51). Silencing of the heparanase gene led to decreased angiogenesis and reduced 
metastasis of tumor cells, directly linking heparanase activity to cancer progression 
(52). Several studies provided evidence that heparin inhibits heparanase activity in 
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vitro, and the inhibition of heparanase activity by heparin correlated with attenuation 
of metastasis (30, 53, 54). Recently it was analyzed whether non-anticoagulant 
heparin treatment affects primarily heparanase activity or inhibits selectin-mediated 
interactions and thereby contributes to reduction of metastasis (45). Heparin 
derivatives showing strong heparanase inhibitory activity significantly reduced the 
metastatic capacity of tumor cells expressing this enzyme. However, P-selectin 
specific heparin derivatives were functional inhibitors of metastasis regardless of 
heparanase expression in the corresponding tumor cells.   
 
VII Cell-cell interactions during metastasis 
Circulating tumor cells are known to interact with platelets, leukocytes and endothelial 
cells. The creation of tumor cell emboli consisting of platelets and leukocytes was 
demonstrated to facilitate metastasis (31, 55-59). Elimination of platelets resulted in 
attenuation of metastasis (56). Furthermore, any interference in platelet-tumor cell 
interactions led to enhanced elimination of tumor cells by NK cells or enhanced 
association of CD11b positive cells, suggesting that the platelet thrombus 
mechanistically “protects” tumor cells from immune response (31, 57, 60). While the 
exact molecular mechanism of platelet-tumor cell interactions remains to be 
identified, several lines of evidence suggest that platelets P-selectin is one of the 
mediators in this process (31, 61, 62).  
Although the presence of leukocytes in tumor cell emboli is widely recognized, their 
role in the process of tumor cell emboli formation remains largely unknown. In 
contrast, the contribution of leukocytes to cancer at sites of primary tumors is well 
described (63, 64). Recent studies provided evidence that the leukocyte recruitment 
to the metastatic environment of tumor cells is critical for cancer progression (32, 65). 
The absence of leukocyte L-selectin led to attenuation of metastasis, thereby directly 
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involving leukocytes in this process. Further analysis has revealed the association of 
granulocytes and monocytes/macrophages with tumor cells in the vasculature (65).  
 
VIII Selectins - vascular cell adhesion molecules  
Selectins are vascular cell adhesion molecules involved in interactions of leukocytes, 
platelets and endothelium within the circulation. The physiological functions of 
selectins are well described in processes like inflammation, immune response and 
hemostasis (66). Selectins mediate the initial contacts of leukocytes with the vascular 
endothelium, which are supported by rapid and reversible interactions with selectin 
ligands - carbohydrates. The family of selectins consists of three members: P- , L- 
and E-selectin (66). P-selectin is present in the storage granules of platelets (-
granules) and the endothelium (Weibel-Palade bodies), thus permitting rapid 
exposure on cell surfaces upon activation. L-selectin is constitutively expressed on 
almost all leukocyte subpopulations. In contrast, E-selectin expression on the surface 
of endothelial cells requires de novo transcription, thus occurring several hours after 
stimulation (66). The physiological selectin ligands consist of various oligosaccharide 
structures such as mucins, glycosaminoglycans and sulfated glycolipids (67). The 
lectin domain of selectins recognizes sialylated, fucosylated lactosamine 
oligosaccharides, which present the terminal structure commonly known as sialyl 
Lewis x (sLex) (66, 67).  
 
IX P- and L-selectins facilitate metastasis 
Selectins are also involved in various pathophysiological processes including cancer 
progression (68). Hematogenous metastasis is the major route of systemic spread for 
carcinomas. Epithelial cells are covered with mucins that line the lumen of inner 
organs and are secreted on the apical side of epithelium. Mucins are high-molecular 
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weight molecules containing a protein core heavily modified with O-linked glycan 
structures (69, 70). Carcinoma cells show altered cell surface glycosylation with 
enhanced presence of sLex or sialyl-Tn oligosaccharide structures on mucins (69-71). 
The positive correlation between sLex expression and poor prognosis, due to 
metastasis, has been demonstrated in colon, gastric, lung, prostate and breast 
cancers (72-79). The entrance of carcinoma cells, carrying abundant selectin ligands, 
into the blood circulation makes them potential partners for selectin-mediated 
interactions with platelet, leukocytes and endothelium. In turn, the constant presence 
of L-selectin on leukocytes together with the rapid expression of P-selectin on 
platelets and endothelium makes selectins the potential mediators for early 
interactions during metastasis (19). 
The evidence that P- and L-selectin contribute to metastasis has been recently 
confirmed in different animal models (31, 33, 65). Although the absence of P- or L-
selectin significantly attenuated metastasis of carcinoma cells, there was virtually no 
metastasis detected in the P- and L-selectin double deficient mice, strongly 
suggesting a synergistic effect of both selectins in this process (32). P-selectin 
deficiency reduced metastasis of carcinomas as well as melanomas (31-33). The 
absence of P-selectin led to a reduction of platelet-tumor cell interactions and tumor 
seeding to the lung vasculature (31). Similarly, the removal of selectin ligands on 
tumor cells also caused decreased platelet-tumor cell emboli formation and 
attenuation of metastasis (31, 32, 60). This P-selectin-mediated formation of platelet-
tumor cell emboli seems to protect tumor cells from elimination by NK cells (57). 
Platelet aggregates were detected also by tumor cells not carrying P-selectin ligands, 
thus it is possible that P-selectin mediates also aggregations of platelets (50). 
In addition, the endothelial P-selectin expression was demonstrated to contribute to 
metastasis (33). Lethal irradiation of P-selectin deficient mice followed by bone 
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marrow reconstitution with wild type cells resulted in mice expressing P-selectin only 
in platelets. A significant reduction of metastasis was observed in such chimeric 
mice, indicating that endothelial activation of endothelium and associated P-selectin 
expression contributes to metastasis.  
The potential involvement of L-selectin in metastasis was tested in L-selectin 
deficient mice (32, 65). Metastatic progression was dependent on L-selectin, because 
the absence of L-selectin resulted in attenuation of metastasis. L-selectin-mediated 
recruitment of leukocytes to vascular tumor cells was associated with an enhanced 
expression of L-selectin ligands surrounding the tumor embolus (65). Furthermore, 
intravenous injection of a function blocking L-selectin antibody following tumor cell 
inoculation resulted in attenuation of metastasis directly indicating that leukocytes 
contribute to the initial steps of metastasis. In conclusion leukocytes may facilitate 
metastasis by potentiating tumor cell extravasation as was previously observed in 
experiments both in vitro and in vivo (80-83). 
 
X Heparin attenuates metastasis by inhibition of selectin interactions 
Heparin affects several processes in the metastatic cascade (Figure 1). To address 
the role of heparin in the process of tumor cell invasion and migration into the blood 
vessels, spontaneous metastatic models, that release metastatic tumor cells into the 
circulation over time are necessary. However, the widely used experimental 
metastasis model makes it possible to obtain insight into the molecular mechanisms 
underlying the initiation phase of metastasis. In particular, the direct injection of tumor 
cells into the blood circulation leads to immediate interaction between tumor cells and 
blood cells, implicating selectins as likely candidates facilitating the early steps of 
hematogenous metastasis. Since the applied heparin is cleared from the circulation 
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within a few hours (31), the other effects of heparin (e.g. effect on angiogenesis) are 
unlikely to participate in this process within this time frame.  
Heparin was shown to efficiently bind to P- and L-selectin (84, 85). Despite no 
structural similarity between heparin and natural selectin ligands, the selectin 
inhibitory effect of heparin is likely explained by clusters of negatively charged 
sulfates and carboxylates recognized by selectins (84). To delineate the 
antimetastatic activity of heparin with respect to selectin inhibition, P- and/or L-
selectin deficient mice were analyzed (31-33, 45, 65). While the absence of either P- 
or L-selectin significantly attenuated metastasis, heparin injection shortly before the 
tumor cell inoculation - “early heparin” further reduced metastasis in L-selectin 
deficient mice (32). This early administration of heparin efficiently inhibited platelet-
tumor cell emboli formation, which are P-selectin dependent (31). However, “early 
heparin” administration did not affect metastasis in P-selectin deficient mice (31-33). 
The presence of heparin in circulation at a point in time when tumor cells are still 
intravascular was shown to attenuate metastasis of tumor cells derived from various 
tissues (30, 31, 33, 35, 65). Indeed, UFH treatment was shown to prevent tumor cells 
interactions with platelets, leukocytes and endothelial cells, thereby reducing tumor 
cell survival within the metastatic microenvironment (31-33, 65). Since attenuation of 
metastasis was achieved also with heparin derivatives without anti-coagulant activity 
and also since heparin showed no effect in P-selectin deficient mice, early heparin 
treatment likely affects primarily P-selectin mediated interactions during early steps of 
metastasis. 
The additional reduction of metastasis achieved by early heparin treatment in the 
absence of L-selectin indicates that the L-selectin-dependent involvement of 
leukocytes is an event subsequent to the initial P-selectin-mediated platelet 
aggregation. This is in agreement with the observation that a temporal inhibition of L-
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selectin several hours after the tumor cell injection resulted in attenuation of 
metastasis comparable to the one seen in L-selectin deficient mice (65). Similarly, 
heparin injection several hours (6-12 h) after the tumor cell injection – “late heparin” 
led to an attenuation of metastasis in P-selectin deficient mice, but had no effect on 
metastasis in L-selectin deficient mice (65). Finally, the evidence that heparin affects 
P- and L-selectin and thereby attenuates metastasis was obtained in mice deficient 
both in P- and L-selectin (PL-sel-/-). Treatment of PL-sel-/- mice either with “early” or 
“late” heparin had no effect on metastasis observed in these mice (32). Interestingly, 
repeated injection of high doses of UFH further reduced metastasis in PL-sel-/- mice 
suggesting that heparin at higher doses may have supplementary activities to the 
selectin inhibition (86). Other recent studies with different LMWH and modified 
heparins demonstrated that their anti-metastatic effect mainly depends on their 
selectin inhibitory capacity (35, 36, 45). Altogether, these findings indicate that 
heparin attenuates metastasis primarily by inhibition of P- and L-selectin interactions 
of tumor cells with the blood cells.  
 
XI Heparin as an antimetastatic treatment 
Hematogenous metastasis of solid tumors is directly or indirectly responsible for most 
cancer-related deaths, yet there is no specific anti-metastatic therapy available (87, 
88). In addition, several studies demonstrated that circulating tumor cells are 
detectable in the circulation of cancer patients (89), while the number of circulating 
tumor cells correlated with poor prognosis (90). Hence tumor cells are present in the 
circulation, where these cells are vulnerable to potential therapies. 
Several prospective clinical trials indicate that LMWH affects cancer progression, and 
this effect cannot be solely ascribed to prevention of thrombo-embolism (23, 24, 27). 
Recently a rationale for a clinical study on heparin treatment of cancer has been 
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proposed (18). To achieve an effective inhibition of P-and L-selectin by heparin 
treatment during the time period from the initial detection of the primary tumor all the 
way through the time of the surgical removal has been suggested. During this period 
tumor cells are in vasculature, thus heparin treatment would be most beneficial to the 
patients. Based on the encouraging results obtained from clinical trials thus far, two 
prospective clinical trials have been recently initiated.  
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Figure Legend: 
Figure 1 Potential mechanisms of heparin implicated in its anti-metastatic 
activity.  
A, Heparin inhibits the angiogenesis within the primary tumor by interfering with 
cytokine signaling and reducing thrombin dependent PAR activation, thereby 
attenuating the intravasation of tumor cells. After the intravasation, tumor cells rapidly 
interact with platelets which protect them from NK cell dependent clearing. These 
interactions are mainly P-selectin-mediated and are efficiently inhibited by heparin. B, 
At distant sites, heparin suppresses the cell-cell interactions via blocking selectin- 
and integrin-mediated interactions. The inhibitory activity of heparin on platelet 
activation and the coagulation cascade is also mediated via antithrombin and release 
of TFPI from endothelial cells. In addition, the homing of tumor cells and the 
recruitment of leukocytes contributing to metastasis is impeded by heparin treatment 
through its blocking effect on chemokine signaling. All these activities hinder the 
arrest of tumor cells in the microvasculature and the generation of a permissive 
microenvironment which promotes the formation of metastatic foci. C, Heparin further 
inhibits the heparanase activity which leads to a decreased invasion and 
extravasation. Heparanase inhibition can additionally reduce the release of matrix 
bound cytokines. A direct effect on cytokine signaling also reduces the proliferation of 
metastatic tumor cells. 
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